Endocannabinoids and pain: Spinal and peripheral analgesia in inflammation and neuropathy

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 66, Issue 2-3, 2002, Pages 243-256

  Rice, A S C ^a   Farquhar Smith, W P ^a   Nagy, I ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; NERVE GROWTH FACTOR; PALMIDROL; ANALGESIC AGENT; CANNABINOID RECEPTOR; DRUG RECEPTOR; ENDOCANNABINOID; ICOSANOID;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ELECTROPHYSIOLOGY; HYPERALGESIA; INFLAMMATION; INFORMATION PROCESSING; MAST CELL DEGRANULATION; MUSCLE SPINDLE AFFERENT NERVE; NEUROPATHY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PAIN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; SPINAL CORD; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM; NERVOUS SYSTEM; PATHOLOGY; SPINE;

ANIMALIA; LAMIINAE;

ANALGESIA; ANALGESICS; ANIMALS; CANNABINOIDS; EICOSANOIDS; ENDOCANNABINOIDS; HUMANS; INFLAMMATION; NERVOUS SYSTEM; PAIN; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SPINE;

EID: 0036019404     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.2001.0362     Document Type: Article

References (144)

1. Cannabinoids and pain
2. Cannabinoids and pain
3. Analgesics: Cannabinoids
4. Biochemistry of the endogenous ligands of cannabinoid receptors
5. 2-Arachidonyl glycerol ether, an endogenous agonist of the cannabinoid CB1 receptor
6. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
7. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat
8. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 agonist palmitoylethanolamide investigated in models of visceral and somatic inflammatory pain
9. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent
10. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents
11. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol
12. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol
13. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction
14. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
15. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)
16. Induction of vanilloid receptor channel activity by protein kinase C
17. Anandamide activates peripheral nociceptors in normal and arthritic knee joints
18. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors
19. A second endogenous cannabinoid that modulates long-term potentiation
20. Characterisation of a second endogenous cannabinoid ligand that modulates long term potentiation (LTP) in hippocampus
21. 2-Arachidonylglycerol and the cannabinoid receptor
22. Liquid chromatographic-mass spectrometric measurement of the endogenous cannabinoid 2-arachidonylglycerol in the spinal cord and peripheral nervous system
23. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells
24. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonylglycerol, on immune function in B6C3F1 mouse splenocytes
25. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide
26. N-(2-Hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-regulating mast cell activation
27. Control of pain initiation by endogenous cannabinoids
28. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder
29. Antinociceptive activity of the endogenous fatty acid amide, palmitoylethanolamide
30. The palmitoylethanolamide and oleamide enigmas: Are these two fatty acid amides cannabimimetic?
31. An entourage effect: Inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity
32. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders
33. Fatty acid amid hydrolase: Biochemistry, pharmacology and therapeutic possibilities for an enzyme hydrolysing anandamide, 2-arachidonylglycerol, palmitoylethanolamide and oleamide
34. Supersensitivity to anandamide and enhanced endogenous cannabinoid signalling in mice lacking fatty acid amide hydrolase
35. Cannabinoid receptor genes
36. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice
37. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
38. CB2 knockout mouse
39. 1 cannabinoid receptor knock out mice
40. Evidence for a new G-protein coupled cannabinoid receptor in mouse brain
41. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study
42. 1
43. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
44. A light and electron microscopic study of the CB1 cannabinoid receptor in the primate spinal cord
45. 1 receptor expression in rat spinal cord
46. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord
47. CB1 receptor localization in rat spinal cord and roots, dorsal root ganglion and peripheral nerve
48. Localization of central cannabinoid CB 1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: A double-label in situ hybridization study
49. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurones
50. Molecular characterization of a peripheral receptor for cannabinoids
51. Cannabinoid receptors CB1 and CB2: A characterization of expression and adenylate cyclase modulation within the immune system
52. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations
53. Local neuro-immune interactions in visceral hyperalgesia: Bradykinin, neurotrophins and cannabinoids
54. Comparison of the pharmacology and signal transduction of the human cannabinoid CB 1 and CB2 receptors
55. Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment
56. Antihyperalgesic effects of spinal cannabinoids
57. CB1 receptor mediated analgesia from the Nucleus Reticdaris Gigantocellularis pars alpha is activated in an animal model of neuropathic pain
58. Distribution of cannabinoid receptor messenger RNA in the human brain: An in situ hybridization histochemistry with oligonucleotides
59. Cannabinoid receptors undergo axonal flow in sensory nerves
60. Actions of cannabinoid receptor ligands on rat cultured sensory neurones: Implications for antinociception
61. The cannabinoid CB 1 receptor is localised predominantly on N52 within the rat dorsal root ganglion
62. Transport and localization of the DRG/ENaC ion channel BNaC1 □ to peripheral mechanosensory terminals of dorsal root ganglia neurons
63. Cannabinoid inhibition of the capsaicin-induced calcuim response in rat dorsal root ganglion neurones
64. Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder
65. Cannabinoid-induced presynaptic inhibition of glutamatinergic EPSCs in sustantia gelatinosa neurons of the rat spinal cord
66. Effects of cannabinoids on neurons in the superficial medulary dorsal horn of the rat
67. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals
68. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto purkinje cells
69. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses
70. Spinal mechanisms of delta 9-tetrahydrocannabinol-induced analgesia
71. Cannabinoid transmission and pain perception
72. 0-1057, a potent water-soluble cannabinoid receptor agonist with antinocieptive properties
73. Cannabinoid-induced antinociception is mediated by a spinal alpha 2-noradrenergic mechanism
74. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia
75. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation
76. Pharmacological studies of nociceptive systems using the C-Fos immunohistochemical technique: An indicator of noxiously activated spinal neurones
77. Expression of spinal Fos after nerve growth factor-induced inflammation of the rat urinary bladder is attenuated by cannabinoids
78. Suppression of noxious stimulus-evoked expression of FOS protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist
79. 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain
80. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors
81. Mechanisms of inflammatory pain: Role of neurotrophins and cannabinoids
82. N-(2-hydroxyethyl) hexadecamide reduces mechanical hyperalgesia following sciatic nerve constriction injury
83. Hyperalgesia due to nerve injury: Role of neutrophils
84. Trophic factors and pain
85. Brain-derived neurotrophic factor is an endogenous modulator of nociceptive responses in the spinal cord
86. Nerve growth factor regulates the expression of bradykinin binding sites on adult sensory neurons via the neurotrophin receptor p75
87. In vivo NGF deprivation reduces SNS expression and TTX-R sodium currents in IB4-negative DRG neurons
88. Nerve growth factor (NGF) differentially regulates the chemosensitivity of adult rat cultured sensory neurons
89. Peripheral cell types contributing to the hyperalgesic action of nerve growth factor in inflammation
90. Mediator release from mast cells by nerve growth factor. Neurotrophin specificity and receptor mediation
91. Local injection of nerve growth factor (NGF) triggers degranulation of mast cells in rat paw
92. Human mast cells express functional trkA and are a source of nerve growth factor
93. Mast cells synthesize, store, and release nerve growth factor
94. Identification of genes differentially expressed by nerve growth factor and neurotrophin-3 dependent sensory neurons
95. Supression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation
96. Nerve growth factor: From neurotrophin to neurokine
97. The effects of endocannabinoids on peripheral NGF-induced neutrophil accumulation in rat skin
98. Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide
99. The cannabinoid system and cytokine network
100. Effect of colchicine on nerve growth factor-induced leukocyte accumulation and thermal hyperalgesia in the rat
101. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes
102. Intraplantar injection of nerve growth factor into the rat hind paw: Local edema and effects on thermal nociceptive threshold
103. Effect of a 5-lipoxygenase inhibitor on nerve growth factor-induced thermal hyperalgesia in the rat
104. Peripheral administration of nerve growth factor in the adult rat produces a thermal hyperalgesia that requires the presence of sympathetic post-ganglionic neurones
105. Nerve growth factor induces plasma extravasation in rat skin
106. Nerve growth factor induced hyperalgesia in the rat hind paw is dependent on circulating neutrophils
107. 1 receptors
108. Palmitoylethanolamide (PEA) attenuates NGF-induced hyperalgesia by reducing neutrophil accumulation via cannabinoid CB2-like receptors
109. Measurement of cutaneous inflammation: Estimation of neutrophil content with an enzyme marker
110. Neurotrophin receptors and nerve growth factor are differentially expressed in adjacent nonneuronal cells of normal and injured tooth pulp
111. Nerve growth factor: A chemotactic factor for polymorphonuclear leukocytes in vivo
112. Inhibition of leukocyte adhesion by the in vivo and in vitro administration of cannabinoids
113. Recent developments in the pathophysiology of acute pain
114. Pain mechanisms and pathways
115. Mechanisms of neuropathic pain
116. The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats
117. Optimal scoring strategies and weights for the formalin test in rats
118. The formalin test: An evaluation of the method
119. HU 308: A specific agonist for CB(2), a peripheral cannabinoid receptor
120. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia
121. The cannabinoid receptor agonist WIN 55,212-2 blocks the development of hyperalgesia produced by capsaicin in rats
122. Are there fundamental differences in the peripheral mechanisms of visceral and somatic pain?
123. The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyperreflexia associated with inflammation of the rat urinary bladder
124. The role of nerve growth factor in a model of visceral inflammation
125. Inflammation of the rat urinary bladder is associated with a referred thermal hyperalgesia which is nerve growth factor dependant
126. Sensitisation of visceral afferents by nerve growth factor in the adult rat
127. 2 receptors
128. Regulation of opioid binding sites in the superficial dorsal horn of the rat spinal cord following loose ligation of the sciatic nerve: Comparison with sciatic nerve section and lumbar dorsal rhizotomy
129. Time-related decreases in mu and delta opioid receptors in the superficial dorsal horn of the rat spinal cord following a large unilateral dorsal rhizotomy
130. Cannabinoid CB1 receptor upregulation in a rat model of chronic neuropathic pain
131. Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture
132. The analgesic effects of R(+)-WIN55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain
133. Pro- and anti-inflammatory cytokine messenger RNA changes in chronic constriction injury model
134. Role of peri-axonal inflammation in the development of thermal hyperalgesia and guarding behavior in a rat model of neuropathic pain
135. Possible role of inflammatory mediators in tactile hypersensitivity in rat models of mononeuropathy
136. The synthetic cannabinoid WIN 55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain
137. SR141716a, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice
138. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity
139. 1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat
140. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat
141. Characterisation of delta9 Tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats
142. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist
143. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor